ArticleNutrition journal2025
Probiotic supplementation on cognitive and other aging-related physiological functions in middle-aged and older adults with mild cognitive impairment (PCAMCI): protocol for a randomized, triple-blinded, placebo-controlled trial.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundEmerging evidence suggests gut microbiota modulation may influence neurocognitive function through the gut-brain axis. Although preliminary studies indicate probiotics' potential benefits for mild cognitive impairment (MCI), well-designed randomized controlled trials remain limited. This protocol paper describes a rigorously designed, registered clinical trial investigating the effects of targeted probiotic supplementation on cognitive and physiological outcomes in MCI participants.
methodsA total of 110 middle-aged and older participants aged 55-80 years with MCI were scheduled to be included in the study, and randomized in a 1:1 ratio to either a probiotic group receiving supplementation consisting of Lactiplantibacillus plantarum ST-III, Lacticaseibacillus rhamnosus KF7, and Lacticaseibacillus paracasei BD5115, or a placebo group with maltodextrin for 12 months. All the participants, researchers, and analysts will remain blinded to the information regarding group allocation in the study. The primary outcome will be the effect of probiotic supplementation on cognitive function, measured by Montreal Cognitive Assessment (the Chinese Beijing Version). The secondary outcomes will include the impact of probiotic supplementation on digestive health, sleep health, facial aging, fundus conditions, olfactory and auditory function, body composition, bone density, and muscle function. Brain magnetic resonance imaging and wearable device including continuous glucose monitor and smart band will also be employed. DISCUSSION: This study will provide some new insights on how probiotic supplementation could impact cognitive function and other aging-related physiological functions in MCI adults and explore the potential underlying mechanisms. The findings may inform the development of strategies to delay cognitive decline by modulating the gut-brain axis in this high-risk population.
trial registrationChiCTR2400084594.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.